AdAlta Ltd (ASX: 1AD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AdAlta Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $6.42 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 3.21 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AdAlta Ltd (ASX: 1AD)
    Latest News

    Woman thinking in a supermarket.
    Consumer Staples & Discretionary Shares

    Up 19% in 2024, is it time to buy or sell Coles shares?

    Let's see the verdict.

    Read more »

    woman in lab coat conducting testing.
    ASX Share Market News

    AdAlta (ASX:1AD) share price rockets 31% on United States FDA update

    The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. Here's all the…

    Read more »

    1AD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AdAlta Ltd

    AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company was founded in 2007 and is headquartered in Bundoora, Australia.

    1AD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Nov 2026 $0.00 $0.00 0.00% 1,039,875 $0.00 $0.00 $0.00
    17 Nov 2026 $0.00 $0.00 0.00% 3,829,659 $0.00 $0.00 $0.00
    12 Nov 2026 $0.00 $0.00 0.00% 332,396 $0.00 $0.00 $0.00
    11 Nov 2026 $0.00 $0.00 0.00% 800,000 $0.00 $0.00 $0.00
    09 Nov 2026 $0.00 $0.00 0.00% 2,768,955 $0.00 $0.00 $0.00
    06 Nov 2026 $0.00 $0.00 0.00% 2,260,222 $0.00 $0.00 $0.00
    04 Nov 2026 $0.00 $0.00 0.00% 4,500,000 $0.00 $0.00 $0.00
    02 Nov 2026 $0.00 $0.00 0.00% 131,990 $0.00 $0.00 $0.00
    30 Oct 2026 $0.00 $0.00 0.00% 38,151,684 $0.00 $0.00 $0.00
    29 Oct 2026 $0.00 $0.00 0.00% 1,675,309 $0.00 $0.00 $0.00
    28 Oct 2026 $0.00 $0.00 0.00% 45,016,546 $0.00 $0.00 $0.00
    27 Oct 2026 $0.00 $0.00 0.00% 324,080 $0.00 $0.00 $0.00
    22 Oct 2026 $0.00 $0.00 0.00% 410,647 $0.00 $0.00 $0.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Dec 2025 Timothy Oldham Buy 1,396,999 $4,889
    Conversion of securities.
    04 Dec 2025 Timothy Oldham Exercise 1,396,999 $4,889
    Conversion of securities.
    26 Nov 2025 Timothy Oldham Expiry 4,929,060 $17,251
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Paul MacLeman Non-Executive ChairmanNon-Executive Director Oct 2019
    Dr MacLeman has 25 years' experience in the life sciences sector a career in veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance. Dr MacLeman is also an advisor
    to PharmaVentures plc. (Oxford, UK) and serves on NFP and government advisory groups.
    Dr Timothy Oldham Managing DirectorChief Executive Officer Oct 2019
    Dr Oldham has 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia.
    Mr Fadi Diab Non-Executive Director Mar 2026
    Mr Diab has 10 years' experience in financial institutions. Mr Diab has experience in corporate governance, strategy, capital markets, mergers and acquisitions companies across the mining, biotechnology and technology sectors.
    Ms Michelle Burke Non-Executive Director Nov 2024
    Ms Burke has 25 years' experience in the life sciences sector, with knowledge in pharma and biotech industries. Ms Burke worked at Bristol-Myers Squibb and SmithKline Beecham. Ms Burke is the industry nominee to the Pharmaceutical Benefits Advisory Committee. Ms Burke serves as an advisor for Proto Axiom Pty Ltd.
    Mr Cameron Jones Chief Financial OfficerCompany Secretary May 2017
    -
    Cameron Jones Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Meurs Group 293,480,026 9.14%
    Sufian Ahmad 287,133,321 8.94%
    Mr David Dominic Pevcic 230,595,264 7.18%
    Sacavic Pty Ltd <Sacavic A/C> 191,108,388 5.95%
    Ms Chunyan Niu 181,969,001 5.67%
    Kobala Investments Pty Ltd <Fernando Edward Family A/C> 124,000,000 3.86%
    Hsbc Custody Nominees (Australia) Limited A/C 2 79,574,880 2.48%
    Scintilla Strategic Investments Limited 75,000,000 2.33%
    Mr Bin Liu 65,000,000 2.02%
    Mrs Ifrah Nishat 62,500,000 1.95%
    Dr Michel Elkhoury 62,161,295 1.94%
    Mr Bilal Ahmad 52,333,333 1.63%
    Mr Dean Brett Blankfield 49,166,667 1.53%
    BNP Paribas Nominees Pty Ltd 39,453,727 1.23%
    Libert Pty Ltd <N & L Muller S/F A/C> 39,166,667 1.22%
    Mrs Shaista Zaffar 37,516,667 1.17%
    Mr Joshua Gordon 31,894,921 0.99%
    CTH Govt Dept SCI IND 27,029,924 0.84%
    Mr Muhammad Salman & Mrs Sajida Akram & Miss Fatima Salman <Kulovall Family S/F A/C> 25,000,000 0.78%
    Mrs Gwen Murray Pfleger <Pfleger Family A/C> 25,000,000 0.78%
    Ponce Pty Ltd <Wexford Arms A/C> 25,000,000 0.78%
    Agha Family Investments Pty Ltd <Agha Family A/C> 23,333,333 0.73%

    Profile

    since

    Note